Chemotherapy-induced peripheral neuropathy is a disabling condition induced by several frequently used chemotherapeutic drugs including the front-line agent oxaliplatin (OXA). Symptoms are predominantly sensory with the development of neuropathic pain. Alternative dosing protocols and treatment discontinuation are the only available therapeutic strategies. The aim of our work was to evaluate the potential of a synthetic derivative of progesterone, 17α-hydroxyprogesterone caproate (HPGC), in the prevention and treatment of OXA-evoked painful neuropathy. We also evaluated glial activation at the dorsal root ganglia (DRG) and spinal cord levels as a possible target mechanism underlying HPGC actions. Male rats were injected with OXA and HPGC following a prophylactic (HPGCp) or therapeutic (HPGCt) scheme (starting either before or after chemotherapy). The development of hypersensitivity and allodynic pain and the expression of neuronal and glial activation markers were evaluated. When compared to control animals, those receiving OXA showed a significant decrease in paw mechanical and thermal thresholds, with the development of allodynia. Animals treated with HPGCp showed patterns of response similar to those detected in control animals, while those treated with HPGCt showed a suppression of both hypersensitivities after HPGC administration. We also observed a significant increase in the mRNA levels of activating transcription factor 3, the transcription factor (c-fos), glial fibrillary acidic protein, ionized calcium binding adaptor protein 1, interleukin 1 beta (IL-1β) and tumor necrosis factor alpha (TNFα) in DRG and spinal cord of OXA-injected animals, and significantly lower levels in rats receiving OXA and HPGC. These results show that HPGC administration reduces neuronal and glial activation markers and is able to both prevent and suppress OXA-induced allodynia, suggesting a promising therapeutic strategy.
drug or combination of drugs used and the dosing regime. 3, 7 In addition, due to recent advances in diagnosis and treatment, the percentage of patients that survive cancer has increased significantly, giving greater relevance to the adverse effects that antineoplasic drugs generate in the long term. 4 Depending on the degree of toxicity generated, the development of CIPN may require dose reduction or early discontinuation of the chemotherapeutic agent, thus conditioning the effectiveness of cancer treatment and the prognosis of the patient. 4 Unfortunately, the course of the neuropathy is variable and, although in many cases it reverts gradually after drug withdrawal, in many others the symptoms persist or actually increase. In the particular case of OXA, the development of both acute neurotoxicity and chronic neuropathy with persistent pain has been described. 5, 6 There is currently no available therapy to effectively manage chemotherapy-induced neuropathic pain. 8 For symptomatic relief, evidence from clinical studies supports a moderate recommendation only for the antidepressant duloxetine. 8, 9 Furthermore, there are no agents recommended for use in the prevention or long lasting suppression of chemotherapy-induced neuropathic pain. 4, 8, 9 Therefore, the search for neuroprotective agents that can both prevent and/or reverse symptoms by acting directly on the maladaptive changes that occur in the nervous system as a result of the exposure to the chemotherapeutic agent is a concrete and compelling need.
In this regard, a more thorough understanding of cellular and molecular contributors to chemotherapy-induced neuronal damage is needed 1, 6 in order to develop effective, mechanism-based disease-modifying interventions. Although primary afferent neurons are the primary target for OXA neurotoxicity, the activation of glial cells, including satellite cells, astrocytes and microglia, at peripheral and central pain processing areas could also be contributing to chronic pain generation. In fact, the role of activated glial cells together with the release of pro-inflammatory mediators that could be in turn-activating pain pathways is becoming increasingly evident in experimental models of chemotherapy-induced neuropathic pain. 10 Previous studies have shown that progesterone (PR), a neuroactive steroid with well-described neuroprotective actions, 11, 12 modulates glial activation and the release of pro-inflammatory mediators and exerts anti-allodynic effects after experimental spinal cord injury. 13, 14 In addition, a prolonged-action synthetic derivative of PR, 17α-hydroxyprogesterone caproate (HPGC), has been shown to reduce neuropathic pain symptoms and improve the functional status of the hand in patients with carpal tunnel syndrome. [15] [16] [17] Therefore, the present study was designed to examine the role of HPGC in the prevention and/or treatment of neuropathic painassociated behaviors in an experimental model of OXA-induced neuropathy. Furthermore, we also investigated the expression of neuronal and glial activation markers at both dorsal root ganglia (DRG) and spinal cord levels, trying to provide insight into the potential target mechanisms underlying the steroid`s protective effects. 19 Thus, in animals receiving OXA + HPGCp, the steroid was administered before and during the chemotherapy cycle, while in animals receiving OXA + HPGCt, the steroid was administered after the antineoplasic cycle had ended.
| MATERIALS AND METHODS

| Animals
For long-term pain evaluation, the following experimental groups were included: OXA + oil (thereafter referred to as OXA); OXA + HPGCp; OXA + HPGCt; saline + oil (thereafter referred to as control (CTL) group). For molecular studies, animals belonging to the following experimental groups were included: OXA + oil (thereafter referred to as OXA); OXA + HPGCp; saline + oil (thereafter referred to as CTL), euthanized 7 days after initiating OXA administration.
| Evaluation of the animals' weight, appearance and changes in posture
In order to monitor the general health of the animals as well as OXA systemic actions, daily body weights were recorded during the whole experimental period. In addition, the existence of evident postural changes, as well as deficient or excessive grooming was evaluated as indirect indicators of spontaneous pain. 20 For this purpose, the animals were weighed daily and the acquisition of antalgic postures, as well as the lack of cleanness of the coat and the presence of alopecic plaques, indicative of deficient or excessive grooming respectively, were analyzed.
For the statistical analysis of the differences in growth curves, the mean weight ± standard error of the mean (SEM) of each experimental group was calculated at each time point evaluated, and the results were analyzed using the repeated measures Friedman test for analysis of variance followed by a test of multiple comparison. Figure 1A correspond to the mean ± SEM. As previously reported, results were analyzed using the Friedman repeated measures of analysis of variance followed by multiple comparison test.
| Assessment of pain behaviors
13,14,21
| Choi test for cold allodynia
Cold sensitivity of the hindpaw to acetone was quantified by paw withdrawal frequency, as originally described by Choi et al. 24 Thus, a drop of 100 μL of acetone was applied to the center of the plantar surface of the paw using a plastic tubule connected to a 1-mL syringe. 13, 14, 21 Acetone was applied five times to each paw at Tissues were frozen and stored at −70 C until further studies were performed.
| Real-time reverse transcription-polymerase chain reaction
Spinal dorsal halves were processed individually while DRG from two animals was pooled together. Samples from the different experimental groups were run at the same time. RNA was extracted using Trizol (Invitrogen Hercules, California), as previously described, 13, 14, 21 and the concentration and purity of total RNA were determined by measuring the optical density at 260 and 280 nm.
Reverse transcription was performed from 2 μg of total RNA using a SuperScript II Rnase H reverse transcriptase kit (Invitrogen). vs CTL from day 10 and P < 0.05 vs OXA from day 12).
| Growth curves of animals belonging to the different experimental groups
When analyzing the animals' body weight, a sustained growth in the control group was observed throughout the experimental period, which began 8 days before the chemotherapy cycle and extended for another 18 days after starting OXA administration. Thus, as shown in On the other hand, OXA-injected animals, regardless of whether they had received HPGC treatment or not, showed attenuation in their weight gain from the beginning of the chemotherapy cycle.
Attenuation that was accentuated in the long term, reaching statistically significant differences with respect to control animals on days The following symbols were used to represent P values: *P < 0.05, **P < 0.01. CTL, control; HPGC, 17α-hydroxyprogesterone caproate; HPGCp, HPGC following a prophylactic; HPGCt, HPGC following a therapeutic; OXA, oxaliplatin FIGURE 3 Relative mRNA levels corresponding to the different studied markers in the lumbar dorsal root ganglia of animals belonging to the different experimental groups, 7 days after starting OXA or saline administration. Data shown correspond to the mean ± SEM and were analyzed using one-way ANOVA and the Newman-Keuls post-test (ns P > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001). ATF3, activating transcription factor 3; c-fos, transcription factor; CTL, control; HPGCp, HPGC following a prophylactic; Iba-1, ionized calcium binding adaptor protein 1; IL-1β, interleukin 1 beta; OXA, oxaliplatin; TNFα, tumor necrosis factor alpha OXA, P > 0.05 vs CTL), in rats that also received HPGC prophylactic administration. 
| Changes in the expression of the proinflammatory cytokines IL-1β and TNFα in lumbar ganglia and spinal cord after OXA and HPGC administration
When analyzing the expression levels of the aforementioned proinflammatory mediators, a significant increase in IL-1β and TNFα mRNA levels was observed, both in L3-L5 DRG (Figure 3 , P < 0.001 vs CTL for L-1β, P < 0.05 vs CTL for TNFα) and in dorsal lumbar spinal cord ( Figure 4 , P < 0.05 vs CTL for L-1β, P < 0.01 vs CTL for TNFα) of animals receiving OXA, 7 days after starting the chemotherapy cycle.
In contrast, in the lumbar ganglia and the dorsal spinal cord of animals receiving OXA and HPGC prophylactic treatment, the expression levels of both cytokines were significantly lower ( Figure 3 , P < 0.001 vs OXA for IL-1β, P < 0.05 vs OXA for TNFα; Figure 4 , P < 0.01 vs OXA for both markers), similar to those detected in control animals ( Figures 3 and 4 , P > 0.05 vs CTL for IL-1β and TNFα in both tissues).
| Levels of expression of c-fos, marker of neuronal activation, in lumbar ganglia and dorsal spinal cord of animals belonging to the different experimental groups
Finally, when evaluating the mRNA levels corresponding to c-fos, a neuronal activation marker, a significant increase was detected in the FIGURE 4 Relative mRNA levels corresponding to the different markers under study in the lumbar dorsal spinal cord of animals belonging to the different experimental groups, 7 days after initiating OXA or saline administration. Data shown correspond to the mean ± SEM and were analyzed using one-way ANOVA and the Newman-Keuls post-test (ns P > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001). ATF3, activating transcription factor 3; c-fos, transcription factor; CTL, control; GFAP, glial fibrillary acidic protein; HPGCp, HPGC following a prophylactic; Iba-1, ionized calcium binding adaptor protein 1; IL-1β, interleukin 1 beta; OXA, oxaliplatin; TNFα, tumor necrosis factor alpha dorsal spinal cord of OXA-injected animals ( Figure 4 , P < 0.01 vs CTL), and significantly lower levels, similar to those detected in control animals ( Figure 4 , P < 0.01 vs OXA, P > 0.05 vs CTL) in the dorsal cord of rats that also received HPGC preventive treatment.
On the contrary, no changes were detected in c-fos expression in L3-L5 DRG of animals receiving either OXA (Figure 3 , P > 0.05 vs CTL) or OXA + HPGCp (Figure 3 , P > 0.05 vs CTL).
| DISCUSSION
The present study shows for the first time that HPGC prophylactic administration is able to prevent chemotherapy-induced mechanical and cold hypersensitivity and allodynia, and that the late administration of the steroid is effective in suppressing the mentioned neuropathic pain-associated symptoms.
As it was already mentioned, CIPN is a frequent and severe adverse side effect of cancer treatment that can be induced after exposure to several chemotherapeutic drugs, including the platinum compound OXA used in the management of various solid tumors, most frequently colorectal cancer. 2, 3, 6, 31 Patients with CIPN experience sensory abnormalities including symptoms of neuropathic pain, such as spontaneous pain and allodynia, mainly distributed in their hands, feet and perioral region. 4, 6, 32 In particular, OXA can induce both acute neurotoxicity after the first few infusions and a chronic neuropathy that can actually worsen after discontinuation, being one of the agents more prone to induce painful symptoms. 6, 31 In correlation with the usual clinical presentation in patients, animals receiving OXA showed a significant reduction in paw mechanical withdrawal threshold, as well as a significant increase in the number of positive responses to cold stimulation, evidencing the development of hypersensitivity to both types of stimuli from the beginning of the chemotherapy cycle and even once it had finished, in the long term.
During the study, we also detected response values indicative of mechanical and cold allodynia in more than half of the animals receiving OXA, being cold allodynia more frequent than its mechanical counterpart, as it has also been described in patients. 4, 6, 31 In the clinical setting, such is the negative impact of this disabling neuropathy on the quality of life of cancer patients, that its development can force chemotherapy dose reduction or early discontinuation, being these the only available strategies to limit the neuropathy. 4, 31 Unfortunately, in this way, cancer patients' response to treatment and survival are threatened. Thus, the evaluation of strategies that could either prevent and/or suppress CIPN-associated symptoms is of upmost relevance. In this study, we have analyzed the effects of the synthetic steroid HPGC, being able to identify therapeutic approaches that were effective in counteracting chemotherapy-induced neuropathic pain.
In fact, animals receiving OXA and treated with HPGC following a prophylactic scheme (before the onset and during chemotherapy) did not develop allodynia and showed patterns of response to both mechanical and thermal stimuli that were similar to those detected in control animals during the whole experimental period. On the other hand, animals receiving OXA and treated with HPGC following a therapeutic scheme (once the chemotherapy cycle was over) developed hypersensitivity to both mechanical and thermal stimuli that was then suppressed by the steroid. In this way, HPGC resulted effective in both the prevention and reversion of pain elicited by OXA exposure.
Interestingly, the steroid was not able to counteract the attenuation of weight gain detected in animals receiving OXA. This significant reduction in body weight confirms the systemic action of the chemotherapeutic agent, whose anorexigenic effects have been already described both in laboratory animals 33 and patients. 34, 35 No changes were detected in the appearance of the animals belonging to any of the experimental groups. They did not acquire antalgic postures nor evidenced deficient or excessive grooming. Although not directly associated with pain, the development of these altered behaviors could be suggestive of spontaneous pain.
HPGC is a synthetic derivative of PR usually used for the treatment of amenorrhea, infertility and misbirth risk. In addition, and related to the condition addressed in this study, three recent clinical trials have shown that the local administration of the steroid effectively alleviates neuropathic pain in patients with mild and moderate carpal tunnel syndrome, 15-17 a peripheral neuropathy that develops due to compression of the median nerve and that causes tingling, numbness, pain and functional deficits of the hand. In these trials, a single local injection of HPGC was able to induce significant and long lasting reduction of pain intensity, as well as to improve the functional status of the hand.
15-17
The present findings in an experimental model of OXA-induced peripheral neuropathy correlate with the beneficial effects observed in patients with carpal tunnel syndrome, thus widening the spectrum of possible clinical applications of the steroid. It is relevant to point out that both the long-term effects (that were maintained until the end of the study, 6 months after the steroid administration) and the lack of local and systemic adverse effects were verified in the mentioned clinical trials. [15] [16] [17] However, at least to our knowledge, the beneficial effects of HPGC administration had not been tested in any other condition, experimental or clinical, of neuropathic pain.
On the contrary, well known are the anti-allodynic effects exerted by PR and its reduced metabolite allopregnanolone, neuroactive steroids with proven neuroprotective and anti-inflammatory actions, 11, 12 in different animal models of neuropathic pain. [36] [37] [38] [39] In particular, we have recently shown that early and sustained PR administration to animals with a sciatic nerve chronic constriction injury 40 or a spinal cord hemisection 13, 14, 21 is able to avoid maladaptive changes leading to central sensitization, thus preventing the development of mechanical and thermal allodynia. 13, 14, 21, 40 However, PR-delayed treatment was not able to suppress well established allodynia, at least after a sciatic nerve constriction 41 or a spinal cord hemisection. 13 In this study, we show that HPGC is capable of both preventing and suppressing neuropathic pain-associated behaviors, thus expanding the possible therapeutic uses of these neuroprotective steroids.
The results here presented also suggest that early HPGC administration is capable of reducing OXA-induced primary afferent neurons damage, as well as glial activation and production of pro-inflammatory mediators both in lumbar DRG and spinal cord, thus probably avoiding the hiperexcitability of pain circuits and resulting in the observed HPGC-mediated attenuation of pain.
The neurotoxic actions of chemotherapy drugs mainly compromise the peripheral nervous system, which lacks the protection provided by the blood brain/spinal barrier, thus rendering an axonopathy due to axonal damage, and a neuropathy in which neuronal bodies in DRG are involved. 6 In this respect, ATF3 is an immediate-early transcription factor whose expression is induced after neuronal injury, being considered a marker of neuronal damage. 42, 43 In fact, we detected increased ATF3 mRNA levels in lumbar DRG of animals receiving OXA, as it has been already shown in other experimental models of peripheral neuropathy such as those associated with diabetes, 44 paclitaxel administration 45, 46 or axotomy. 43 In this last model, the authors also evaluated ATF3 expression in neurons from the dorsal horn, not being able to detect the trans-synaptic induction of the transcription factor, 43 observation that correlates with our findings. Interestingly, in the dorsal spinal cord of animals receiving HPGC, ATF3 expression levels were lower than those detected in control animals. Although unexpected, this result could be related to the fact that ATF3 gene expression is positively regulated by the transcription factor activating protein 1 (AP-1), 47 whose transcriptional activity is decreased in the presence of PR. 48 In spite of the fact that HPGC's effect on AP-1 transcriptional activity has not been studied, the observed ATF3 downregulation could possibly be related to a PR-like action of the synthetic steroid.
We also detected a significant increase in the expression of c-fos, a proto-oncogen that is immediately induced after synaptic input and is therefore considered a marker of neuronal activity, 49 in the dorsal spinal cord of OXA-treated animals. Similarly, increased c-fos expression has been described in superficial and deep dorsal horn neurons either after innocuous stimulation in naive animals or after noxious stimulation in nerve injury models, thus representing a widely used marker of both nociception and central sensitization. 49 In our experimental model of OXA-induced neuropathy, we did not detect any changes in DRG c-fos expression, as it does not occur in another experimental model of peripheral nervous system damage, such as diabetic neuropathy. 44 It is now a well consolidated concept that not only neurons but also glial cells at both peripheral and central pain processing areas contribute to neuropathic pain generation. 50, 51 After nervous system injury, glial cell activation and the production of proinflammatory mediators, such as the pro-inflammatory cytokines IL-1β, IL-18, IL-6 y TNFα, can directly modulate the activity of neurons and other glial cells, contributing to the development and maintenance of chronic pain. 50, 51 In fact, modulating the neuroinflammatory process has emerged as a promising option for the treatment of neuropathic pain. 51 Interestingly, in the recent years, neuroinflammation has been proposed as a major mechanism underlying CIPN-associated pain. 10 In fact, we detected a significant increase in the mRNA levels of GFAP and Iba-1 (markers of satellite glial cells/astrocyes and microglila cells/macrophages, respectively), both in the lumbar DRG and dorsal spinal cord of animals receiving OXA. These findings, together with the increased expression of pro-inflammatory cytokines, confirm previous reports showing that the administration of the chemotherapeutic agent triggers glial activation both peripherally and centrally. 10 In this regard, we detected increased levels of expression of IL-1β
and TNFα in the lumbar ganglia and spinal cord of OXA-treated animals. Previous studies have shown that after nerve injury, the expression of these cytokines increases in response to neuronal hyperactivity, 52 participating in glial to neuron communication and activating pain pathways. 53 In the particular case of TNFα, an increase in its expression, 54 as well as in the mRNA levels of its receptors tumor necrosis factor receptor 1 (TNFR1) and tumor necrosis factor receptor 2 (TNFR2), 55 localized both in neurons and glial cells, has been observed in DRG of animals with compressive injury of the sciatic nerve 54 or its dorsal roots. 55 It has been postulated that TNFα exerts neurotoxic actions by activating its TNFR1 receptor and neuroprotective actions by activating TNFR2, although there is no final consensus. 56 On the other hand, the actions of IL-1β are mediated by its functional receptor interleukin 1 beta receptor I (IL-1RI), also expressed in both glial cells and neurons. 57, 58 In this way, both cytokines can directly act on neuronal cells to modulate their activity. In particular, by activating the signaling pathway of IL-1RI 58, 59 and TNFR1, 60 both IL-1β 59 and TNFα In the lumbar DRG and dorsal spinal cord of the animals receiving OXA and HPGC prophylactic treatment significantly lower expression levels of the aforementioned neuronal and glial markers and proinflammatory cytokines were detected, suggesting that the steroid early administration is capable of preventing chemotherapy-triggered neurotoxicity and glial activation, and revealing a disease-modifying effect. These neuroprotective and anti-inflammatory actions could contribute to the anti-allodynic effects observed in the animals that received the steroid.
In relation to the signaling pathways possibly involved in the neuroprotective and anti-inflammatory effects observed after HPGC administration, it is well known that the steroid can activate both PR and glucocorticoid (GR) receptors, 61 expressed by neurons and glial cells. These receptors belong to the superfamily of nuclear receptors and act as ligand-activated transcription factors, regulating gene expression by binding to specific DNA-responsive elements. Although the regulation by HPGC of the genes here evaluated has not yet been described, it is already known that the expression of ATF3, 62 c-fos, 63 GFAP, 64, 65 Iba1, 66 IL-1β 65, 67 and TNFα 65, 67 can be regulated by PRand/or GR-dependent mechanisms, thus enabling their regulation by the steroid.
It is important to note that during its endogenous metabolism, the caproate ester is not cleaved, thus neither 17α-hydroxyprogesterone (natural metabolite) nor PR are generated. 61 Therefore, the actions observed in this study would have been directly mediated by HPGC.
The anti-inflammatory effects mediated by both GR and PR in the nervous system are widely recognized. 67, 68 When activated by GRs, GR interacts with the transcription factor nuclear factor kappa-lightchain-enhancer of activated B cells (NFκB), repressing NFκB-dependent genes. 68 Similarly, in the presence of its natural ligand, PR is able to decrease NFκB transcriptional activity by repressing its expression 69 and/or generating an inactive PR-NFκB heterodimer. 70 After an injury of the nervous system, NFκB is one of the main transcription factors regulating glial activation and the production of a large array of pro-inflammatory mediators, 71, 72 including IL-1β and TNFα. In fact, previous studies have suggested that the regulation of pro-inflammatory cytokines and enzymes exerted by PR in the injured nervous system would be mediated by the modulation, PR dependent, of the transactivation potential of NFκB. 13, 65 Although these mechanisms have not yet been studied in the presence of HPGC, it would be feasible to postulate their participation in the effects here observed, and will be the subject of future studies. In fact, both neurons and glial cells of the peripheral and central nervous system express PR 36, 37 and GR, 67 making these cells sensitive targets to HPGC actions.
In summary, our results show that the administration of the synthetic steroid HPGC exerts disease-modifying effects, attenuating OXA-induced neuronal and glial activation, and is able to both prevent and suppress the hypersensitivity and allodynia triggered by the antineoplasic drug. We hope that these findings may contribute to reduce the incidence and improve the management of chemotherapy-derived neuropathic pain, resulting in a better quality of life of cancer patients.
